Bismuth subcitrate, metronidazole, and tetracycline and Busulfan interaction
Bismuth subcitrate, metronidazole, and tetracycline and Busulfan: the Bismuth subcitrate, metronidazole, and tetracycline prescribing label flags this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Bismuth subcitrate, metronidazole, and tetracycline (Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride) label · effective 2026-04-13
Do not administer bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride concomitantly with busulfan unless the benefit outweighs the risk.
Busulfan: Increased busulfan serum concentrations; avoid concomitant use, monitor for busulfan toxicity.
Busulfan Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity.
If no therapeutic alternatives to bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride are available, and concomitant administration with busulfan is medically needed, monitor for busulfan toxicity and busulfan plasma concentrations and adjust the busulfan dose accordingly [see Drug Interactions ( 7.7 )] .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.